Activist Investor Ramius Capital Wins Two Board Seats
| January 6th, 2011 | ||
| SurModics, a drug delivery pharmaceutical company, announced that it has resolved a dispute with Ramius Capital Group by agreeing to grant two board seats to Ramius. Ramius Capital, a New York-based activist investor, demanded three board seats in response to the company’s "failed growth investments, failed acquisitions and excessive spending.” Jeffrey Smith, Chief Investment Officer of Ramius, and Dr. David Dantzker of Wheatley Partners joined the SurModics board Tuesday in place of John Meslow and Kenneth Keller. In response to the appointments, Jeffrey Smith said, “We are pleased to have worked constructively with SurModics to reach this settlement. Dr. Dantzker and I look forward to working diligently and constructively with our fellow Board members to enhance value for all SurModics shareholders and we are confident that our collective experience will prove valuable to the Company.“ Ramius currently holds a 12% stake in SurModics. | ||
See Source | ||
For Detailed Investor Profiles on these Investors, click below: |
Ramius Capital Group |
Related People: Jeffrey Smith;
Related Entities: Cowen Group Inc. (NASDAQ: COWN);
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles
View Comments (1) | Add a Comment |
1 Comments
by james on April 24th, 2012
I think this is so amazing that you are able to get this seats. You will benefit so much from these seats. Great job on this. bad side effects of paxil
More Recent Headlines
Polar Capital’s Discovery Fund to Close |
A Strong December Leads to Double Digit Gains for Paulson’s Funds |
Galleon Co-Founder Starting Firm |
FrontPoint Announces New $1 Billion Fund |
Quantedge Capital Looks to Double Assets Under Management |
David Einhorn Announces Favorite Long Position for 2011 |
Alleged Hedge Fund Tipster Remains Jailed |
The Big Hedge Fund Killing in For Profit Education |
Greenlight Capital’s David Einhorn fears another crisis |
Teall Edds and Stuart Wilson’s Orchard Capital Partners outperforms |
